Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 14/20 | 0.72 |
| ▸ | AR | P10275 | 10/20 | 0.72 |
| ▸ | NR3C2 | P08235 | 9/20 | 0.72 |
| ▸ | PGR | P06401 | 16/20 | 0.72 |
| ▸ | ESR1 | P03372 | 6/20 | 0.72 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6291144 | 0.91 | NR3C1 (0.74) | NR3C1ARNR3C2PGRESR1 | |
| SCHEMBL6291591 | 0.89 | NR3C1 (0.75) | NR3C1ARNR3C2PGRESR1 | |
| SCHEMBL6295018 | 0.89 | PGR (0.74) | NR3C1ARNR3C2PGRESR1 | |
| SCHEMBL6290327 | 0.88 | PGR (0.78) | NR3C1ARNR3C2PGRESR1 | |
| SCHEMBL6294953 | 0.87 | NR3C1 (0.80) | NR3C1ARNR3C2PGRESR1 | |
| SCHEMBL6291126 | 0.86 | NR3C1 (0.75) | NR3C1ARNR3C2PGRESR1 | |
| SCHEMBL6291115 | 0.86 | PGR (0.78) | NR3C1ARNR3C2PGRESR1 | |
| SCHEMBL4174333 | 0.85 | NR3C1 (0.81) | NR3C1ARNR3C2PGRESR1 | |
| SCHEMBL6998522 | 0.85 | NR3C1 (0.74) | NR3C1ARNR3C2PGRESR1 | |
| Acetic Acid SCHEMBL6291027 | 0.85 | NR3C1 (0.74) | NR3C1ARNR3C2PGRESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073703-A1 | Glucocortiocoid-selective antinflammatory agents | ABBOTT LABORATORIES AND LIGAND PHARMACEUTICALS INCORPORATED | 2003-04-17 | — | — | US | claimed |
| EP-1299392-A2 | GLUCOCORTIOCOID-SELECTIVE ANTIINFLAMMATORY AGENTS | Abbott Laboratories (US) | 2003-04-09 | — | — | EP | claimed |
| US-6506766-B1 | A pharmaceutical composition for use in treating inflammation, immune, autoimmune, and inflammatory diseases in a mammal by selectively modulating the activation, repression, agonism, and antagonism effects of the mammal's glucocorticoid | ABBOTT LABORATORIES | 2003-01-14 | — | — | US | claimed |
| EP-1053239-B1 | GLUCOCORTICOID-SELECTIVE ANTI-INFLAMMATORY AGENTS | ABBOTT LAB (US) | 2003-01-08 | — | — | EP | claimed |
| WO-2002002565-A2 | GLUCOCORTIOCOID-SELECTIVE ANTIINFLAMMATORY AGENTS | ABBOTT LABORATORIES (US) | 2002-01-10 | — | — | WO | claimed |
| US-6951942-B2 | Glucocorticoid-selective anti-inflammatory agents | ABBOTT LABORATORIES (US) | 2005-10-04 | — | — | US | disclosed |
| US-20030073703-A1 | Glucocortiocoid-selective antinflammatory agents | ABBOTT LABORATORIES AND LIGAND PHARMACEUTICALS INCORPORATED | 2003-04-17 | — | — | US | disclosed |
| EP-1299392-A2 | GLUCOCORTIOCOID-SELECTIVE ANTIINFLAMMATORY AGENTS | Abbott Laboratories (US) | 2003-04-09 | — | — | EP | disclosed |
| US-6506766-B1 | A pharmaceutical composition for use in treating inflammation, immune, autoimmune, and inflammatory diseases in a mammal by selectively modulating the activation, repression, agonism, and antagonism effects of the mammal's glucocorticoid | ABBOTT LABORATORIES | 2003-01-14 | — | — | US | disclosed |
| EP-1053239-B1 | GLUCOCORTICOID-SELECTIVE ANTI-INFLAMMATORY AGENTS | ABBOTT LAB (US) | 2003-01-08 | — | — | EP | disclosed |
| WO-2002002565-A2 | GLUCOCORTIOCOID-SELECTIVE ANTIINFLAMMATORY AGENTS | ABBOTT LABORATORIES (US) | 2002-01-10 | — | — | WO | disclosed |
| EP-1053239-A1 | GLUCOCORTICOID-SELECTIVE ANTI-INFLAMMATORY AGENTS | ABBOTT LABORATORIES (US) | 2000-11-22 | — | — | EP | disclosed |
| WO-1999041256-A1 | GLUCOCORTICOID-SELECTIVE ANTI-INFLAMMATORY AGENTS | ABBOTT LABORATORIES (US) | 1999-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073703-A1 | Glucocortiocoid-selective antinflammatory agents | NR3C1, GPR119, MC2R | NR3C1 1/4885AR 1816/4885NR3C2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.